Title: Effect of montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Version: 2 Date: 21 Jan 2025
Reviewer's report:
- “Ulcerative colitis (UC) is an autoimmune disease”
No, it is an immune-mediated disease
- Use lower case for Montelukast, Leukotrienes, Mesalamine
- “acute severe UC based on Truelove and Witt’s criteria [18], and attainment of clinical
remission using 1 mg/kg prednisolone”
ASUC should be treated with intravenous methylprednisolone and not with oral prednisolone
- “The number of patients in each group was calculated using PASS software, considering the
result of the previous study [8], and by the presumption of a type I error of 5%, type II error of
20%, and drop-out rate of 20%. Based on this information, we need 90 patients in each group”
What percentage of primary outcome did you expect in the two groups?
- 42.07, 27.25 95% CI: 26.17-28.32 weeks) and placebo group (mean: 20.88; 95% CI: 19.36,
20.40 weeks
Only 1 decimal digit
- Once you have defined an abbreviation, always us it (for example in ulcerative colitis)
- “The first limitation concerns not assessing the histopathological remission.”
Endoscopic remission
Title: Effect of montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Version: 2 Date: 21 Jan 2025
Reviewer's report:
- “Ulcerative colitis (UC) is an autoimmune disease”
No, it is an immune-mediated disease
- Use lower case for Montelukast, Leukotrienes, Mesalamine
- “acute severe UC based on Truelove and Witt’s criteria [18], and attainment of clinical
remission using 1 mg/kg prednisolone”
ASUC should be treated with intravenous methylprednisolone and not with oral prednisolone
- “The number of patients in each group was calculated using PASS software, considering the
result of the previous study [8], and by the presumption of a type I error of 5%, type II error of
20%, and drop-out rate of 20%. Based on this information, we need 90 patients in each group”
What percentage of primary outcome did you expect in the two groups?
- 42.07, 27.25 95% CI: 26.17-28.32 weeks) and placebo group (mean: 20.88; 95% CI: 19.36,
20.40 weeks
Only 1 decimal digit
- Once you have defined an abbreviation, always us it (for example in ulcerative colitis)
- “The first limitation concerns not assessing the histopathological remission.”
Endoscopic remission
Please review this paper.
user
Title: Effect of montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Version: 2 Date: 21 Jan 2025
Reviewer's report:
- “Ulcerative colitis (UC) is an autoimmune disease”
No, it is an immune-mediated disease
- Use lower case for Montelukast, Leukotrienes, Mesalamine
- “acute severe UC based on Truelove and Witt’s criteria [18], and attainment of clinical
remission using 1 mg/kg prednisolone”
ASUC should be treated with intravenous methylprednisolone and not with oral prednisolone
- “The number of patients in each group was calculated using PASS software, considering the
result of the previous study [8], and by the presumption of a type I error of 5%, type II error of
20%, and drop-out rate of 20%. Based on this information, we need 90 patients in each group”
What percentage of primary outcome did you expect in the two groups?
- 42.07, 27.25 95% CI: 26.17-28.32 weeks) and placebo group (mean: 20.88; 95% CI: 19.36,
20.40 weeks
Only 1 decimal digit
- Once you have defined an abbreviation, always us it (for example in ulcerative colitis)
- “The first limitation concerns not assessing the histopathological remission.”
Endoscopic remission
assistant